{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:43:07Z","timestamp":1782506587736,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"St. John's University Research Seed Grant","award":["579-1110-7002"],"award-info":[{"award-number":["579-1110-7002"]}]},{"name":"Guangdong scientific and technological international collaborative foundation","award":["2013B051000046"],"award-info":[{"award-number":["2013B051000046"]}]},{"name":"Guangzhou scientific technology and innovation foundation","award":["201601010008"],"award-info":[{"award-number":["201601010008"]}]},{"name":"Guangzhou scientific technology and innovation foundation","award":["201504010038"],"award-info":[{"award-number":["201504010038"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.canlet.2016.09.025","type":"journal-article","created":{"date-parts":[[2016,10,9]],"date-time":"2016-10-09T17:57:46Z","timestamp":1476035866000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia"],"prefix":"10.1016","volume":"383","author":[{"given":"Pranav","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishil J.","family":"Kathawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuya","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoKun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.09.025_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.canlet.2016.09.025_bib3","first-page":"169","article-title":"Chronic myelogenous leukemia: update on biology and treatment","volume":"13","author":"Faderl","year":"1999","journal-title":"Oncol. (Williston Park)"},{"key":"10.1016\/j.canlet.2016.09.025_bib4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: a concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.09.025_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2016.09.025_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2016.09.025_bib7","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2016.09.025_bib8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1073\/pnas.83.6.1807","article-title":"Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia","volume":"83","author":"Erikson","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2016.09.025_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.09.025_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.09.025_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0145-2126(01)00197-7","article-title":"Bcr-Abl variants: biological and clinical aspects","volume":"26","author":"Advani","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/325635a0","article-title":"A\u00a0novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"325","author":"Chan","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.09.025_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: the new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2016.09.025_bib14","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.09.025_bib15","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2016.09.025_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.canlet.2016.09.025_bib17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571 cancer therapy","volume":"293","author":"Barthe","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.09.025_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.09.025_bib19","first-page":"625","article-title":"Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients","volume":"9","author":"Gambacorti-Passerini","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Silva","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17425255.2016.1145655","article-title":"Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer","volume":"12","author":"Gupta","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.canlet.2016.09.025_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2016.09.025_bib23","first-page":"7149","article-title":"Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)","volume":"62","author":"La Rosee","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib24","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In\u00a0vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib25","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A\u00a0rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.canlet.2016.09.025_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.canlet.2016.09.025_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1749-6632.1964.tb40725.x","article-title":"Studies of the Philadelphia chromosome in patients with chronic myelogenous leukemia","volume":"113","author":"Frei","year":"1964","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2016.09.025_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","article-title":"Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review","volume":"93","author":"Yang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2016.09.025_bib29","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","article-title":"Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.09.025_bib30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2007-0170","article-title":"Therapy options in imatinib failures","volume":"13","author":"Ramirez","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2016.09.025_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.09.025_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2014.03.012","article-title":"HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","volume":"348","author":"Yun","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.09.025_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.18632\/oncotarget.2837","article-title":"HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation","volume":"6","author":"Kim","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2016.09.025_bib35","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.09.025_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.09.025_bib37","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2016.09.025_bib38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2016.09.025_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0300-483X(02)00460-2","article-title":"Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis","volume":"181\u2013182","author":"Pietenpol","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.canlet.2016.09.025_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2007.10.012","article-title":"CDK inhibitors in cancer therapy: what is next?","volume":"29","author":"Malumbres","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2016.09.025_bib41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12935-014-0137-1","article-title":"A\u00a0polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathway","volume":"14","author":"Cao","year":"2014","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2016.09.025_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1357-2725(99)00088-6","article-title":"Role of reactive oxygen species in apoptosis: implications for cancer therapy","volume":"32","author":"Mat\u00e9s","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2016.09.025_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic. Biol. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516305675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516305675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T14:18:10Z","timestamp":1601129890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516305675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0304383516305675"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.09.025","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}